At the Gladstone-UCSF Institute of Genomic Immunology, experts in immunology, synthetic biology, human genetics and CRISPR genome engineering are joining forces to push the boundaries of what’s possible. To overcome cancer, they are learning how to precisely control human immune cells and re-engineer them to become living and genetically-programmable drugs. Investigators at the Parker Institute for Cancer Immunotherapy at Gladstone Institutes are using the latest genomic technologies to understand what governs the function of immune cells and help design next-generation immunotherapy approaches for clinical translation. Alexander Marson, MD, PhD | Director All Investigators Related Announcement, Our Impact, Research Update New CAR-T Approach Shows Promise for Lymphoma Patients Announcement PICI Young Investigator Retreat 2019 Research Update Colorectal cancer genetics study sheds light on why some patients are resistant to treatment Announcement, Cancer Research Heroes PICI Celebrates Carl H. June, MD Announcement, Our Impact PICI Network Researchers at SITC Spring Scientific Announcement, Cancer Research Heroes PICI Honors CAR T-cell Pioneer Carl H. June, MD Announcement, Our Impact PICI Network Researchers at #KSCancerImmuno23 Announcement PICI Network Presenters at #KScelltherapy23 Our Impact 2022 Year in Review
Research Update Colorectal cancer genetics study sheds light on why some patients are resistant to treatment